Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study | Synapse
March 3, 2026
Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study
Key Points
Metastatic breast cancer patients receiving second-line treatment show varied responses, requiring tailored strategies.
Some patients exhibit improved outcomes with alternative therapies following CDK4/6 inhibitors, suggesting personalized care.
Observational analysis across multiple centers assesses treatment effectiveness using clinical data and outcomes.
Insights may enhance current treatment protocols for HR-positive and HER2-negative breast cancer patients.